Allarity Therapeutics files 1-for-30 reverse stock split, reduces authorized shares to 250M

Allarity Therapeutics, Inc.

Stockholders approved 1-for-30 reverse split at Sept 3 annual meeting; effective Sept 11, 2024.
Authorized common shares reduced from 750M to 250M via Sixth Certificate of Amendment.
Board also amended 2021 Equity Plan to increase shares reserved from ~2.2M to ~10.6M (pre-split).
Directors Gerald W. McLaughlin and Laura E. Benjamin re-elected to Class II.
Trading symbol ALLR unchanged; no fractional shares, rounding up.

item 3.03 item 5.03 item 5.02 item 5.07 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.